Cell-based therapy for the pulmonary system

Abstract

Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.

1 . A process for alleviating or inhibiting the progression of mechanically induced acute lung injury in a mammalian patient comprising administration of syngeneic or allogeneic or autologous mesenchymal stem cells, smooth muscle cells, fibroblast cells or a combination thereof to the lung by injection into the pulmonary circulation of the mammalian patient suffering from the disorder wherein the administration results in alleviation or inhibition of the progression of the acute lung injury. 
     
     
         2 . The process of  claim 1 , wherein said cells have been transformed in vitro to express a transgene. 
     
     
         3 . The process of  claim 1  wherein the cells are skin fibroblast cells. 
     
     
         4 . The process of  claim 1  wherein the cells are allogenic. 
     
     
         5 . The process of  claim 1  wherein the cells are autologous. 
     
     
         6 . The process of  claim 2  wherein the transformation is through electroporation with angiopoietin-1 cloned into a plasmid vector. 
     
     
         7 . The process of  claim 1 , wherein the acute lung injury is lung inflammation, septal edema, alveolar inflammation, endothelial inflammation or a combination thereof. 
     
     
         8 . The process of  claim 1 , wherein the acute lung injury is ARDS. 
     
     
         10 . The process of  claim 2 , wherein the transgene is vascular endothelial growth factor, fibroblast growth factor, angiopoietin, hemoxygenase, transforming growth factor, hepatic growth factor, endothelial nitric oxide synthase, Angiopoietin-1, prostaglandin I synthase (PGIS) hypoxia inducible factor, or a combination thereof. 
     
     
         11 . The process of  claim 10  wherein the transgene is endothelial nitric oxide synthase. 
     
     
         12 . The process of  claim 10 , wherein the transgene is vascular endothelial growth factor. 
     
     
         13 . The process of  claim 10  wherein the transgene is PGIS. 
     
     
         14 . The process of  claim 10  wherein the transgene is Ang-1. 
     
     
         15 . The process of  claim 1 , wherein the mechanical injury is ventilation induced lung injury. 
     
     
         16 . A mechanical lung injury alleviating therapeutic comprising mesenchymal stem cells, smooth muscle cells, fibroblast cells or a combination thereof, wherein the therapeutic is delivered intra arterially or intravenously. 
     
     
         17 . The therapeutic of  claim 16 , wherein the mesenchymal stem cells, smooth muscle cells, fibroblast cells or a combination thereof have been transformed with a transgene. 
     
     
         18 . The therapeutic of  claim 17 , wherein the transgene is vascular endothelial growth factor. 
     
     
         19 . The therapeutic of  claim 17 , wherein the transgene is Ang-1. 
     
     
         20 . The therapeutic of  claim 16 , where the lung injury is ARDS.